Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vepdegestrant by Arvinas for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Vepdegestrant by Arvinas for Metastatic Breast Cancer: Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
Vepdegestrant by Arvinas for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Vepdegestrant is under clinical development by Arvinas and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Negative...
Risk adjusted net present value: What is the current valuation of Arvinas's Vepdegestrant?
Vepdegestrant is a small molecule commercialized by Arvinas, with a leading Phase III program in Human Epidermal Growth Factor Receptor...